ProPhase Labs, Inc. Increase (Decrease) in Other Operating Assets and Liabilities, Net
ProPhase Labs, Inc. (PRPH) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $138.00 thousand for the 12-month period ending 2017-12-31, per its 10-K/A filed 2018-08-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2018-08-20
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2016-12-31 was $569.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2016-09-30 was $85.00K, a 93.66% decline year-over-year.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2016-06-30 was $290.00K, a 28.89% increase year-over-year.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for the quarter ending 2016-03-31 was -$397.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2017 was $138.00K, a 74.77% decline from fiscal 2016.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2016 was $547.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2015 was -$147.00K.
- ProPhase Labs, Inc. increase (decrease) in other operating assets and liabilities, net for fiscal 2014 was -$123.00K, a 239.77% decline from fiscal 2013.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|---|
| 2017-12-31 | $138.00K 10-K/A · filed 2018-08-20 | |||
| 2016-12-31 | $569.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-08-20 | $654.00K derived: sum of 2 quarters · filed 2018-08-20 | $944.00K derived: sum of 3 quarters · filed 2018-08-20 | $547.00K 10-K/A · filed 2018-08-20 |
| 2016-09-30 | $85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $375.00K derived: sum of 2 quarters · filed 2016-11-14 | -$22.00K 10-Q · filed 2016-11-14 | -$828.00K derived: sum of 4 quarters · filed 2018-08-20 |
| 2016-06-30 | $290.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$107.00K 10-Q · filed 2016-08-11 | -$913.00K derived: sum of 3 quarters · filed 2018-08-20 | $427.00K derived: sum of 4 quarters · filed 2018-08-20 |
| 2016-03-31 | -$397.00K 10-Q · filed 2016-05-13 | -$1.20M derived: sum of 2 quarters · filed 2018-08-20 | $137.00K derived: sum of 3 quarters · filed 2018-08-20 | $362.00K derived: sum of 4 quarters · filed 2018-08-20 |
| 2015-12-31 | -$806.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-08-20 | $534.00K derived: sum of 2 quarters · filed 2018-08-20 | $759.00K derived: sum of 3 quarters · filed 2018-08-20 | -$147.00K 10-K/A · filed 2018-08-20 |
| 2015-09-30 | $1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $1.56M derived: sum of 2 quarters · filed 2016-11-14 | $659.00K 10-Q · filed 2016-11-14 | $1.23M derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-06-30 | $225.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$681.00K 10-Q · filed 2016-08-11 | -$113.00K derived: sum of 3 quarters · filed 2017-02-24 | $973.00K derived: sum of 4 quarters · filed 2017-02-24 |
| 2015-03-31 | -$906.00K 10-Q · filed 2016-05-13 | -$338.00K derived: sum of 2 quarters · filed 2017-02-24 | $748.00K derived: sum of 3 quarters · filed 2017-02-24 | -$190.00K derived: sum of 4 quarters · filed 2017-02-24 |
| 2014-12-31 | $568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $1.65M derived: sum of 2 quarters · filed 2017-02-24 | $716.00K derived: sum of 3 quarters · filed 2017-02-24 | -$123.00K 10-K · filed 2017-02-24 |
| 2014-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $148.00K derived: sum of 2 quarters · filed 2015-11-13 | -$691.00K 10-Q · filed 2015-11-13 | -$130.00K derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-06-30 | -$938.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$1.78M 10-Q · filed 2015-08-12 | -$1.22M derived: sum of 3 quarters · filed 2016-03-29 | $883.00K derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-03-31 | -$839.00K 10-Q · filed 2015-05-13 | -$278.00K derived: sum of 2 quarters · filed 2016-03-29 | $1.82M derived: sum of 3 quarters · filed 2016-03-29 | $1.26M derived: sum of 4 quarters · filed 2016-03-29 |
| 2013-12-31 | $561.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $2.66M derived: sum of 2 quarters · filed 2016-03-29 | $2.10M derived: sum of 3 quarters · filed 2016-03-29 | $88.00K 10-K · filed 2016-03-29 |
| 2013-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.54M derived: sum of 2 quarters · filed 2014-11-13 | -$473.00K 10-Q · filed 2014-11-13 | -$145.00K derived: sum of 4 quarters · filed 2015-03-27 |
| 2013-06-30 | -$561.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$2.57M 10-Q · filed 2014-08-12 | -$2.24M derived: sum of 3 quarters · filed 2015-03-27 | -$1.60M derived: sum of 4 quarters · filed 2015-03-27 |
| 2013-03-31 | -$2.01M 10-Q · filed 2014-05-12 | -$1.68M derived: sum of 2 quarters · filed 2015-03-27 | -$1.04M derived: sum of 3 quarters · filed 2015-03-27 | -$1.13M derived: sum of 4 quarters · filed 2015-03-27 |
| 2012-12-31 | $328.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $968.00K derived: sum of 2 quarters · filed 2015-03-27 | $884.00K derived: sum of 3 quarters · filed 2015-03-27 | -$269.00K 10-K · filed 2015-03-27 |
| 2012-09-30 | $640.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $556.00K derived: sum of 2 quarters · filed 2013-11-13 | -$597.00K 10-Q · filed 2013-11-13 | -$1.63M derived: sum of 4 quarters · filed 2014-03-27 |
| 2012-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | -$1.24M 10-Q · filed 2013-08-13 | -$2.27M derived: sum of 3 quarters · filed 2014-03-27 | -$806.00K derived: sum of 4 quarters · filed 2014-03-27 |
| 2012-03-31 | -$1.15M 10-Q · filed 2013-05-10 | -$2.19M derived: sum of 2 quarters · filed 2014-03-27 | -$722.00K derived: sum of 3 quarters · filed 2014-03-27 | -$882.00K derived: sum of 4 quarters · filed 2014-03-27 |
| 2011-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $431.00K derived: sum of 2 quarters · filed 2014-03-27 | $271.00K derived: sum of 3 quarters · filed 2014-03-27 | -$81.00K 10-K · filed 2014-03-27 |
| 2011-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-14 | $1.30M derived: sum of 2 quarters · filed 2012-11-14 | $951.00K 10-Q · filed 2012-11-14 | $1.53M derived: sum of 4 quarters · filed 2013-03-28 |
| 2011-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$512.00K 10-Q · filed 2012-08-13 | $63.00K derived: sum of 3 quarters · filed 2013-03-28 | -$117.00K derived: sum of 4 quarters · filed 2013-03-28 |
| 2011-03-31 | -$352.00K 10-Q · filed 2012-05-11 | $223.00K derived: sum of 2 quarters · filed 2013-03-28 | $43.00K derived: sum of 3 quarters · filed 2013-03-28 | |
| 2010-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-28 | $395.00K derived: sum of 2 quarters · filed 2013-03-28 | $201.00K 10-K · filed 2013-03-28 | |
| 2010-09-30 | -$180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$374.00K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | -$194.00K 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $45.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |